Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 USD | +4.28% | -8.88% | -34.78% |
Mar. 25 | Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol | DJ |
Mar. 25 | Sector Update: Health Care Stocks Steady Premarket Monday | MT |
Financials (USD)
Sales 2024 * | 265M | Sales 2025 * | 406M | Capitalization | 369M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | 60M | EV / Sales 2024 * | 1.39 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.91 x |
P/E ratio 2024 * |
-4.63
x | P/E ratio 2025 * |
10.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Esperion Therapeutics, Inc.
1 day | +4.28% | ||
1 week | -8.88% | ||
Current month | -27.24% | ||
1 month | -6.25% | ||
3 months | -3.47% | ||
6 months | +143.14% | ||
Current year | -34.78% |
Managers | Title | Age | Since |
---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 20-12-14 |
Director of Finance/CFO | 38 | 19-12-31 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 22-04-27 | |
J. Carroll
CHM | Chairman | 74 | 22-05-31 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 20-03-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 237 M€ | +0.46% | - | |
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1.95 | +4.28% | 7,345,904 |
24-04-18 | 1.87 | +1.63% | 6,038,838 |
24-04-17 | 1.84 | -3.66% | 3,718,668 |
24-04-16 | 1.91 | -1.29% | 6,181,222 |
24-04-15 | 1.935 | -9.58% | 6,822,648 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.78% | 354M | |
+24.60% | 672B | |
+24.08% | 550B | |
-5.63% | 351B | |
+15.37% | 317B | |
+7.38% | 292B | |
+3.26% | 211B | |
+0.78% | 203B | |
-9.69% | 144B | |
-6.63% | 141B |
- Stock Market
- Equities
- ESPR Stock